Women Infertility – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Women Infertility – Pipeline Review, H1 2017’, provides an overview of the Women Infertility pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Women Infertility

– The report reviews pipeline therapeutics for Women Infertility by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Women Infertility therapeutics and enlists all their major and minor projects

– The report assesses Women Infertility therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Women Infertility

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Women Infertility

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

AbbVie Inc

Addex Therapeutics Ltd

AlphaMab Co Ltd

APAvadis Biotechnologies Srl

ASKA Pharmaceutical Co Ltd

Astellas Pharma Inc

Bayer AG

Dong-A Socio Holdings Co Ltd

Dongkook Pharmaceutical Co Ltd

ElexoPharm GmbH

EndoCeutics Inc

Enteris BioPharma Inc

Evotec AG

Ferring International Center SA

Forendo Pharma Ltd

Glycotope GmbH

Isifer AB

Kissei Pharmaceutical Co Ltd

Lipicard Technologies Ltd

Livzon Pharmaceutical Group Inc

Luye Pharma Group Ltd

Merck & Co Inc

Navya Biologicals Pvt Ltd

Nippon Shinyaku Co Ltd

Nora Therapeutics Inc

ObsEva SA

Ogeda SA

Orphagen Pharmaceuticals Inc

Pangen Biotech Inc.

Pantec Biosolutions AG

PharmaEssentia Corp

Philogen SpA

Repros Therapeutics Inc

Richter Gedeon Nyrt

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

TocopheRx Inc

ValiRx Plc

Viramal Ltd

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Women Infertility Overview 9

Women Infertility Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Women Infertility Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Women Infertility Companies Involved in Therapeutics Development 31

4P Therapeutics LLC 31

AbbVie Inc 31

Addex Therapeutics Ltd 32

AlphaMab Co Ltd 32

APAvadis Biotechnologies Srl 33

ASKA Pharmaceutical Co Ltd 33

Astellas Pharma Inc 34

Bayer AG 34

Dong-A Socio Holdings Co Ltd 35

Dongkook Pharmaceutical Co Ltd 36

ElexoPharm GmbH 36

EndoCeutics Inc 37

Enteris BioPharma Inc 37

Evotec AG 38

Ferring International Center SA 38

Forendo Pharma Ltd 39

Glycotope GmbH 39

Isifer AB 40

Kissei Pharmaceutical Co Ltd 40

Lipicard Technologies Ltd 41

Livzon Pharmaceutical Group Inc 41

Luye Pharma Group Ltd 42

Merck & Co Inc 42

Navya Biologicals Pvt Ltd 43

Nippon Shinyaku Co Ltd 43

Nora Therapeutics Inc 44

ObsEva SA 44

Ogeda SA 45

Orphagen Pharmaceuticals Inc 45

Pangen Biotech Inc. 46

Pantec Biosolutions AG 46

PharmaEssentia Corp 47

Philogen SpA 47

Repros Therapeutics Inc 48

Richter Gedeon Nyrt 48

SK Chemicals Co Ltd 49

Takeda Pharmaceutical Company Ltd 49

TocopheRx Inc 50

ValiRx Plc 50

Viramal Ltd 51

Zydus Cadila Healthcare Ltd 51

Women Infertility Drug Profiles 52

acolbifene hydrochloride + GnRH Agonist + prasterone Drug Profile 52

ADX-68692 Drug Profile 53

AKP-501 Drug Profile 54

ASP-1707 Drug Profile 55

barusiban Drug Profile 56

BAY-1128688 Drug Profile 57

BAY-1158061 Drug Profile 58

Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis Drug Profile 59

Biosimilar 5 for Infertility and Oncology Drug Profile 60

Biosimilar 6 for Infertility, Oncology and Immunology Drug Profile 61

Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology Drug Profile 62

choriogonadotropin alfa biosimilar Drug Profile 63

choriogonadotropin alfa biosimilar Drug Profile 64

danazol Drug Profile 65

Drug 1 for Endometriosis Drug Profile 66

Drug 2 for Endometriosis Drug Profile 67

Drug 3 for Endometriosis Drug Profile 68

Drug 4 for Endometriosis Drug Profile 69

Drug 5 for Endometriosis Drug Profile 70

Drug to Antagonize P2X3 for Endometriosis Drug Profile 71

Drug to Inhibit C-Jun for Endometriosis Drug Profile 72

Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health Drug Profile 73

Drugs for Endometriosis and Uterine Fibroids Drug Profile 74

EC-313 Drug Profile 75

elagolix sodium Drug Profile 76

EVE-104 Drug Profile 81

FE-999310 Drug Profile 82

fezolinetant Drug Profile 83

follicle stimulating hormone biosimilar Drug Profile 86

follitropin alfa biosimilar Drug Profile 87

follitropin alfa biosimilar Drug Profile 89

follitropin alfa biosimilar Drug Profile 90

follitropin delta Drug Profile 91

FP-5677 Drug Profile 93

FSH-GEX Drug Profile 94

goserelin biosimilar Drug Profile 96

goserelin ER Drug Profile 97

Isifera Drug Profile 98

kisspeptin-54 Drug Profile 99

KLH-2109 Drug Profile 100

KN-015 Drug Profile 102

leuprolide acetate Drug Profile 103

LM-001 Drug Profile 104

LM-002 Drug Profile 105

LT-6121 Drug Profile 106

menotropins Drug Profile 107

MIA-602 Drug Profile 108

MK-8389 Drug Profile 109

Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility Drug Profile 110

NAV-013 Drug Profile 111

NS-580 Drug Profile 112

NT-100 Drug Profile 113

OBE-001 Drug Profile 115

PEG-FSH Drug Profile 118

Peptide to Agonize FSH Receptor for Women Infertility Drug Profile 119

Peptides for Endometriosis and Hepatic Tumor Drug Profile 120

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor Drug Profile 121

PGL-1001 Drug Profile 122

PGL-2001 Drug Profile 123

progesterone Drug Profile 124

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome Drug Profile 125

relugolix Drug Profile 126

SKI-2670 Drug Profile 129

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health Drug Profile 130

Small Molecules for Female Infertility Drug Profile 131

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology Drug Profile 132

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis Drug Profile 133

Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology Drug Profile 134

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis Drug Profile 135

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers Drug Profile 136

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis Drug Profile 137

SR-16234 Drug Profile 138

STI-2833 Drug Profile 139

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology Drug Profile 140

TAK-448 Drug Profile 141

telapristone acetate Drug Profile 143

Tetravil Drug Profile 152

TOP-001 Drug Profile 154

TOP-002 Drug Profile 155

triptorelin Drug Profile 156

triptorelin acetate ER Drug Profile 157

triptorelin biosimilar Drug Profile 158

VAL-201 Drug Profile 159

VAL-301 Drug Profile 164

vilaprisan Drug Profile 165

VPE-001 Drug Profile 166

VPEA-004 Drug Profile 167

Women Infertility Dormant Projects 168

Women Infertility Discontinued Products 171

Women Infertility Product Development Milestones 172

Featured News & Press Releases 172

Appendix 183

Methodology 183

Coverage 183

Secondary Research 183

Primary Research 183

Expert Panel Validation 183

Contact Us 183

Disclaimer 184

List of Tables

List of Tables

Number of Products under Development for Women Infertility, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Women Infertility Pipeline by 4P Therapeutics LLC, H1 2017

Women Infertility Pipeline by AbbVie Inc, H1 2017

Women Infertility Pipeline by Addex Therapeutics Ltd, H1 2017

Women Infertility Pipeline by AlphaMab Co Ltd, H1 2017

Women Infertility Pipeline by APAvadis Biotechnologies Srl, H1 2017

Women Infertility Pipeline by ASKA Pharmaceutical Co Ltd, H1 2017

Women Infertility Pipeline by Astellas Pharma Inc, H1 2017

Women Infertility Pipeline by Bayer AG, H1 2017

Women Infertility Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Women Infertility Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Women Infertility Pipeline by ElexoPharm GmbH, H1 2017

Women Infertility Pipeline by EndoCeutics Inc, H1 2017

Women Infertility Pipeline by Enteris BioPharma Inc, H1 2017

Women Infertility Pipeline by Evotec AG, H1 2017

Women Infertility Pipeline by Ferring International Center SA, H1 2017

Women Infertility Pipeline by Forendo Pharma Ltd, H1 2017

Women Infertility Pipeline by Glycotope GmbH, H1 2017

Women Infertility Pipeline by Isifer AB, H1 2017

Women Infertility Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Women Infertility Pipeline by Lipicard Technologies Ltd, H1 2017

Women Infertility Pipeline by Livzon Pharmaceutical Group Inc, H1 2017

Women Infertility Pipeline by Luye Pharma Group Ltd, H1 2017

Women Infertility Pipeline by Merck & Co Inc, H1 2017

Women Infertility Pipeline by Navya Biologicals Pvt Ltd, H1 2017

Women Infertility Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Women Infertility Pipeline by Nora Therapeutics Inc, H1 2017

Women Infertility Pipeline by ObsEva SA, H1 2017

Women Infertility Pipeline by Ogeda SA, H1 2017

Women Infertility Pipeline by Orphagen Pharmaceuticals Inc, H1 2017

Women Infertility Pipeline by Pangen Biotech Inc., H1 2017

Women Infertility Pipeline by Pantec Biosolutions AG, H1 2017

Women Infertility Pipeline by PharmaEssentia Corp, H1 2017

Women Infertility Pipeline by Philogen SpA, H1 2017

Women Infertility Pipeline by Repros Therapeutics Inc, H1 2017

Women Infertility Pipeline by Richter Gedeon Nyrt, H1 2017

Women Infertility Pipeline by SK Chemicals Co Ltd, H1 2017

Women Infertility Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Women Infertility Pipeline by TocopheRx Inc, H1 2017

Women Infertility Pipeline by ValiRx Plc, H1 2017

Women Infertility Pipeline by Viramal Ltd, H1 2017

Women Infertility Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Women Infertility Dormant Projects, H1 2017

Women Infertility Dormant Projects, H1 2017 (Contd..1), H1 2017

Women Infertility Dormant Projects, H1 2017 (Contd..2), H1 2017

Women Infertility Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Women Infertility, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports